Increased risk of both bleeding and thrombosis creates a confusing clinical picture; there is little empirical evidence to help decide whether to pursue anticoagulation pharmacotherapy in this population.
Although patients with an indication for anticoagulation and stable mild to moderate liver disease may be in a state of balance of pro-and anticoagulant factors 7 and, therefore, be at lower risk for undergoing anticoagulation, those with advanced or decompensated disease are likely poor candidates. In these patients, clinicians might consider using warfarin after carefully considering risks and benefits. However, no models currently exist to help clinicians identify patients with liver disease who might safely tolerate warfarin.
Therefore, this study addresses 2 questions: first, what convenient markers of disease severity among patients with chronic liver disease might allow clinicians to risk stratify such patients with regard to their likelihood of achieving good anticoagulation control? Second, do these same markers of disease severity also predict rates of major hemorrhage among such patients? Answering these questions will help clinicians better individualize care for patients with liver disorders with indications for oral anticoagulation therapy.
Methods Database
The Veterans AffaiRs Study to Improve Anticoagulation database included 103 897 patients receiving oral anticoagulation with warfarin from 100 sites of care in the Veterans Health Administration (VA) between October 1, 2006 and September 30, 2008. 10 In general, patients were considered to be receiving warfarin when they were in possession of warfarin as dispensed by a VA pharmacy or when they had INR determinations at least every 6 weeks. Patients with liver disease were specifically required to be in possession of warfarin at all times, defined as the duration of the most recent prescription plus a 30-day grace period. Merely having regular INR determinations did not suffice to establish a patient with liver disease as being on warfarin because INR testing may be used to monitor liver disease. 10 For this study, patients were excluded during their first 6 months on warfarin; thus, this is a database of experienced warfarin users. We performed similar analyses during the inception period (months 0-6 of warfarin therapy). Results were extremely similar to the main analyses (Tables I-IV are available in the Data Supplement) . Patients undergoing anticoagulation for mechanical heart valves were also excluded because of varying target of INR ranges, which made it impossible to calculate percentage time in therapeutic range. This study was approved by the Institutional Review Board of the Bedford VA Medical Center.
Definition of Liver Disease
Patients were defined as having liver disease if there was record ≥1 of the International Classification of Diseases-Ninth Revision (ICD-9) codes for chronic liver disease, recorded either in the inpatient or outpatient setting, during the study period (ICD-9 codes are available in the Data Supplement). Portal vein thrombosis (452.x) was not among the conditions used to establish a diagnosis of liver disease; nor was it an indication for anticoagulation therapy in any of the patients studied. In fact, only 53 of the 1763 patients with liver disease experienced portal vein thrombosis during the study. Therefore, the focus of this study was on patients anticoagulated for other indications who had coincident chronic liver disease.
In preliminary investigations, we examined whether specific ICD-9 codes for liver disease were associated with anticoagulation control (ex: 571.2 alcoholic cirrhosis versus 571.9 chronic liver disease NOS). We found no important differences among patients based on specific diagnostic codes, or how many times these codes were recorded, or they appeared in the inpatient or the outpatient setting (data not shown). Thus, we used all such codes equally to indicate chronic liver disease and shifted our focus to laboratory values as potential markers of disease severity and risk among patients with any coded liver disease.
Dependent Variable: Anticoagulation Control
The percentage of time within therapeutic range (TTR) was calculated for each patient with Rosendaal method, which uses linear interpolation to assign an INR value to each day between 2 successive observed INR values. 11 TTR is calculated as the percentage of time during which the interpolated INR values lie between 2 and 3; it ranges between 0% to 100%.
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Dependent Variable: Major Hemorrhagic Events
The algorithm for identifying major hemorrhage was based, in part, on the definition of the International Society of Thrombosis and Haemostasis.
12 ICD-9 codes were used to identify candidate events that occurred while the patients were undergoing anticoagulation using both VA and Medicare data. 13 Events were retained if they occurred while a patient was receiving warfarin, as described above, and fulfilled ≥1 of 4 conditions: (1) associated with death within 30 days, (2) associated with blood transfusion, (3) associated with bleeding into a critical anatomic site, or (4) cited as the main reason for a hospitalization (primary diagnostic code). Approximately 16% of candidate events were retained as major hemorrhages by this definition although this percentage was much higher for events likely to be severe (eg, diverticula of colon with hemorrhage, 46%) and much lower for events less likely to be severe (eg, hematuria, 4%). Patients were censored after the first bleeding event; therefore, all analyses were time to first hemorrhagic event. Subsets of major hemorrhage, including intracranial and fatal hemorrhages, were initially examined; however, the number of such events was not sufficient to support the analyses and these data are not presented. For all analyses of major
WHAT IS KNOWN
• Patients with liver disease may require anticoagulation for unrelated conditions, but little is known about its safety in these patients.
• Novel anticoagulants are not approved for use in patients with liver disease; thus, warfarin will likely continue to be the predominant agent used in this patient population.
• Understanding the risks of warfarin use in patients with liver disease would help inform clinical decision making.
WHAT THE STUDY ADDS
• Patients with chronic liver disease receiving warfarin have poorer anticoagulation control and more bleeding, even after controlling for bleeding risk factors.
• However, these effects are not uniform, and specific laboratory values predict poor outcomes.
• A 4-point scoring system using albumin and creatinine can risk-stratify patients with liver disease in regard to risk of major hemorrhage while taking warfarin.
hemorrhage, patients with Medicare Advantage (n=15 642 or 15% of patients) were excluded because of concern for missing data because these patients do not generate itemized bills to Medicare.
Independent Variables: Measures of the Severity of Liver Disease
We used the mean value of several laboratory values to distinguish severity of disease among patients with liver disease. These laboratory tests included serum albumin, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol, and creatinine. We also examined other ways to define these variables, including the worst value (such as the highest AST or the lowest albumin) and the second-worst value. Because these results were not meaningfully different from our main results, we do not show them. These laboratories are readily available and are often used by clinicians to characterize severity and progression of liver disease. Albumin is often low in patients with poor nutritional status and liver disease. In addition, albumin is part of the Child-Pugh score for predicting mortality in patients with liver disease.
14,15 Low total cholesterol is associated with decompensated liver disease and Child-Pugh class. 16 Bilirubin is a part of the Model for EndStage Liver Disease score for stratifying patients for transplant in liver disease. 17 Renal function is important because hepatorenal syndrome is a feared complication of advanced liver disease, and creatinine contributes to the Model for End-Stage Liver Disease score. In addition to creatinine, we also examined estimated glomerular filtration rate computed according to the Modification of Diet in Renal Disease (MDRD) study formula. 18 The 2 measures were closely correlated; creatinine alone predicted both outcomes somewhat better than estimated glomerular filtration rate and was therefore retained. AST and ALT are transaminases associated with metabolic processes of liver damage and inflammation of parenchymal cells and are often elevated in patients with liver disease. We divided these variables into strata based on their univariate distributions and their bivariate relationships with TTR.
Covariates: Risk Factors for Bleeding
In addition to the bleeding analysis, we controlled for other factors that have been validated as part of the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score for predicting hemorrhagic events in patients undergoing anticoagulation for atrial fibrillation. 19 This score incorporates predictors of bleeding risk, including hypertension, chronic liver disease, chronic kidney disease, substance abuse, age, labile INR control, history of stroke, history of bleeding, and the use of antiplatelet medications. 19 For the present study, hypertension, substance abuse, and history of stroke were obtained using ICD-9 codes. We included age and TTR as a covariate for this analysis to capture labile INR control. Because we included creatinine as part of our risk score, we did not include chronic renal disease as a covariate. History of bleeding and the use of antiplatelet agents were not available, but we controlled for the remainder of the available variables and sought to better define the predictors surrounding liver disease.
Statistical Analyses
We examined the ability of laboratory values and covariates to predict TTR, first individually, and then in combination. Similarly, we examined the ability of these laboratory values to predict major hemorrhage. For bivariate tests, we used ANOVA, t test, or χ 2 , as appropriate. We performed multiple regression analyses, linear regression (for the TTR outcome), or Cox Proportional Hazards Model (for the major hemorrhage outcome). We checked the proportional hazards assumption using the method of Schoenfeld residuals, and there was no evidence of major violation. To determine whether liver disease itself increases the risk of hemorrhage independent of anticoagulation control, we controlled for age in all analyses and additionally the other bleeding risk factors in some analyses. We modeled age and TTR as categories rather than continuous variables. We internally validated our final model using split sample validation. We created a data set with a 1:1 ratio of patients with liver disease and patients without, and then used a split 50/50 of this data set for training and validation of a model to predict patient-level TTR. All analyses were performed using SAS, version 9.3.
Results
Characteristics of Patients With Liver Disease
Of the 103 897 patients receiving warfarin, 1763 (1.7%) had chronic liver disease; the baseline characteristics of the patients with and without liver disease are summarized in Table 1 . Notably, patients with liver disease were an average of 5 years younger than those without liver disease and had more comorbid disease, including chronic pulmonary and renal disease, heart failure, and newly diagnosed cancer. They were 3 times as likely to have alcohol or substance abuse, had more mental health disorders, took more medications, and were hospitalized more often.
Anticoagulation Control Among Patients With Liver Disease
Patients with liver disease had a mean TTR of 53.5% as compared with patients without underlying liver disease with a mean of 61.7%. Patients with liver disease did not demonstrate any clear directional tendency to be either above or below therapeutic range. Increasing levels of AST, creatinine, and bilirubin were associated with poorer TTR, as well as lower levels of total cholesterol and albumin (Table 2) .
Hemorrhagic Events Among Patients With Liver Disease
Patients with any sort of liver disease had increased incidence of major hemorrhage (Table 3) . We observed 153 168 patient years among 86 492 patients, with a total of 4525 major hemorrhagic events. The age-adjusted hazard ratio (HR) for major hemorrhage was elevated among patients with liver disease when compared with those without (HR, 2.02; P<0.001). Controlling for anticoagulation control and other bleeding risk factors attenuated this effect only slightly (HR, 1.80; P<0.001). Higher mean creatinine, AST, bilirubin, and lower cholesterol, and albumin were all associated with more hemorrhagic events. These effects were only slightly attenuated and remained statistically significant after adjustment for bleeding risk covariates (Table 3) .
Clinical Prediction Tool for Bleeding Risk.
When all candidate predictors were combined into a single Cox model, only creatinine and albumin persisted as meaningful predictors of bleeding risk. Therefore, we developed a simple tool for clinicians to estimate the risk of anticoagulation in patients with chronic liver disease using these 2 variables (Tables 4 and 5 ); the addition of AST, ALT, bilirubin, or cholesterol did not enhance the ability of the model to predict hemorrhagic events. Our 4-point composite score was formulated as follows: patients received 1 point each for mildly abnormal albumin (2.5-3.49 g/dL) or creatinine (1.01-1.99 mg/dL), and 2 points each for severely abnormal albumin (<2.5 g/dL) or creatinine (≥2 mg/dL). This composite score, which assigned each patient a risk score between 0 and 4 points, predicted both anticoagulation control and hazard for major hemorrhage (Table 6) . When compared with patients without liver disease, those with a score of zero had only a modest decline in TTR (56.7%) and no significant increase in hemorrhagic events (HR, 1.16; P=0.59). Those with a score of 2 had moderately decreased TTR (50.0%) and more hemorrhages (HR, 2.92; P<0.001), whereas those with a score of 4 had poor anticoagulation control (29.4%) and many more hemorrhages (HR, 8.53; P<0.001). The hazard for hemorrhage remained significant and was only mildly attenuated after controlling for anticoagulation control and other known bleeding risk factors.
In the 50/50 split sample validation of the full model, the R 2 only decreased from R 2 =0.129302 to R 2 =0.124814 between the training and validation sets, which we feel demonstrates good validation of the model.
Discussion
Using data from the VA, we looked for predictors of anticoagulation control and major hemorrhagic events among >1700 patients with chronic liver disease receiving warfarin for indications unrelated to their liver disease. As might be expected, the entire cohort of patients with liver disease had poorer anticoagulation control and an elevated hazard for major hemorrhage when compared with patients without liver disease. However, our study demonstrates that these effects are not uniform, and a simple score derived from albumin and creatinine can meaningfully risk-stratify these patients with liver disease, especially with regard to their risk for major hemorrhage. This finding may have considerable clinical use, by offering a simple, readily available indicator of a patient's likelihood to succeed on traditional vitamin K antagonist treatment.
Albumin may be a general marker of health and nutritional status; it is known to decrease with age and critical GFR indicates glomerular filtration rate. *Patients with valvular heart disease or mechanical heart valves were excluded from the study.
illness and predict mortality in elderly hospitalized patients. 20 Specifically for liver disease, albumin is a well-established marker of synthetic function of the liver and part of ChildPugh model to predict mortality. 14, 15 Patients with chronic liver disease tend to have lower serum albumin, and it has been suggested that conformational changes in the molecule and may cause diminished binding ability and a change in body distribution of albumin. 21 Impaired renal function with advanced liver disease and hemorrhagic risk is a multifactorial relationship. Chronic hepatitis is associated with glomerulonephritis, albuminuria, and progression of existing renal disease, as well as places patients at risk for acute kidney injury because of physiological changes that affect the circulation and kidney perfusion, 22 and hepatorenal syndrome is a complication of advanced liver disease. Furthermore, the elevation of creatinine above the normal range may suggest advanced liver disease; normal renal function may be an underestimate in patients with liver disease because they tend to have baseline creatinine lower than the general population because of volume distribution, accumulation of extracellular fluid, malnutrition, edema, lower lean body mass, and ascites. 22 Colinearity may explain why the other variables added little to the model, although individually each had some effect on both TTR and hemorrhagic events. Low levels of cholesterol are likely associated closely with albumin because both are associated with diminished synthetic function of the liver. The elevated transaminases, AST and ALT, are also likely closely associated with liver injury, but generally alone are not predictive of decompensated disease.
The fact that patients with hepatic disease and a normal albumin (≥3.5) and normal renal function (creatinine, <1.0) have similar anticoagulation control and a similar risk of hemorrhagic events when compared with those without liver disease suggests that this model may be helpful for clinicians to identify patients who, despite having chronic liver disease, are still appropriate candidates for warfarin therapy. Conversely, patients with higher scores of 2, 3, or especially 4 points had considerably poorer outcomes, both in terms of anticoagulation control and hemorrhagic events. Using this model, clinicians may wish to categorize these patients at highest risk prospectively and may offer such patients warfarin only for compelling indications and follow these patients especially closely. Although not externally validated using a separate data set, we offer the 4-point model in Tables 4 and 5 as the best available This article has certain compelling strengths. Foremost among these is the fact that we examined outcomes of care among >1700 patients with liver disease who received ongoing warfarin therapy. This would only be possible with a database of this size and detail and provides valuable information and evidence where little or none previously existed. However, some limitations should also be noted. First, the study population of veterans was mostly men, included only patients undergoing anticoagulation for non-liver-related reasons, and may not fully reflect a general population of patients with liver disease. Second, the study does not consider patients with valvular heart disease because the variation in target therapeutic range in these patients makes it difficult to calculate TTR. Third, we assessed major hemorrhagic events using automated data rather than chart review, though our algorithm is the result of careful development. 13 Fourth, although the model controls for many known risk factors for bleeding, we were unable to control for antiplatelet pharmacotherapy, thrombocytopenia, baseline INR, or previous hemorrhage before the study period. Fifth, we considered neither strokes nor recurrent venous thromboembolic events because these outcomes are difficult to assess from automated data alone. [23] [24] [25] Therefore, the examination of definitive outcomes is limited to major hemorrhage. Furthermore, we were not able to compare the outcomes of patients with liver disease with an indication for anticoagulation who did not receive warfarin to those who did receive warfarin. Finally, although our model seems likely to be clinically useful, it has not been validated in a separate population. Its use for selecting patients for therapy would ideally be tested in a prospective study, where outcomes are compared among patients selected for anticoagulation using our proposed model and to others selected according to usual practice. 26, 27 In conclusion, we examined a large database of VA patients receiving anticoagulation with warfarin for varied indications. Patients with liver disease, taken as a group, had notably poor anticoagulation control and an elevated risk for major hemorrhage. However, these effects were not uniform, and a simple 4-point risk score based on serum albumin and creatinine was able to meaningfully risk-stratify these patients with regard to the major hemorrhage. Clinical decision making on anticoagulation in patients with liver disease will continue to be challenging, but the evidence that this study provides may inform better decisions.
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